You are here: Industry Insights > Bristol-Myers Squibb

News List

Bristol-Myers Squibb to lay off 149 as Wallingford, Connecticut, site nears closure fiercepharma
July 18, 2018
Following an earlier layoff round affecting 107 employees, Bristol-Myers Squibb is cutting an additional 149 staffers at its Wallingford, Connecticut, R&D site, with the aim to completely close it by the end of this year.
Bristol-Myers Squibb looks to sell French OTC unit which could bring $1.8B fiercepharma
July 09, 2018
Add Bristol-Myers Squibb to the list of Big Pharmas doing consumer health reevaluations these days. After announcing a review last month, the U.S. drugmaker is looking to sell its French consumer health business, Upsa, according to Reuters.
Bristol-Myers Squibb drops phase 3 trials of $800M IDO drug fiercebiotech
May 02, 2018
Bristol-Myers Squibb has pulled two phase 3 clinical trials of the IDO1 inhibitor it acquired through an $800 million takeover of Flexus.
Janssen, Bristol-Myers Squibb Team Up to Develop Therapy biospace
April 18, 2018
Janssen Pharmaceuticals has teamed up with Bristol-Myers Squibb to drive BMS-986177, a Factor XIa (FXIa) inhibitor, into Phase II development for the study of secondary stroke prevention and major thrombotic conditions.
Bristol-Myers Squibb's Opdivo, Yervoy combination cuts risk of progression, death by 42 percent in lung cancer study firstwordpharma
April 17, 2018
Bristol-Myers Squibb announced Monday that the combination of Opdivo and Yervoy reduced the risk of progression or death by 42 percent versus chemotherapy in first-line advanced non-small-cell lung cancer patients whose tumours have high tumour mutation b
Bristol-Myers Squibb, Johnson & Johnson ink deal to co-develop Factor XIa inhibitors firstwordpharma
April 17, 2018
Bristol-Myers Squibb and Johnson & Johnson announced Monday a global collaboration on a Factor XIa (FXIa) inhibitor programme
Bristol-Myers Squibb Shares Drop on Positive Lung Cancer Trial biospace
April 17, 2018
Bristol-Myers Squibb announced initial positive data from its Phase III CheckMate 227 clinical trial of Opdivo (nivolumab) plus low-dose Yervoy (ipilimumb) combination in first-line advanced non-small cell lung cancer (NSCLC) with high tumor mutational bu
Pfizer Boss Ian Read Claims They Won't Buy Bristol-Myers Squibb or Make Any Other Big Deals biospace
April 16, 2018
There has been speculation for several years whether Pfizer Inc. would consider buying Bristol-Myers Squibb. That appears to have been laid to rest by comments made by Pfizer’s chief executive officer, Ian Read.
Bristol-Myers Squibb and Harvard Stem Cell Institute Team Up biospace
April 13, 2018
Bristol-Myers Squibb and the Harvard Fibrosis Network, part of the Harvard Stem Cell Institute, have launched a collaboration to discover and develop new therapies for fibrotic diseases.
GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patie biospace
March 14, 2018
GRYT Health, and Bristol-Myers Squibb Company today announced a strategic pilot

Previous page 1 2 3 4 5 6 7 8 9 10 Next page